DDInter915 DDInter1676
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Indacaterol {u} (Compound) resembles {v} (Compound) Procaterol
Indacaterol {u} (Compound) treats {v} (Disease) asthma
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Indacaterol (Compound) resembles Procaterol (Compound)
Indacaterol (Compound) treats asthma (Disease)
Indacaterol (Compound) binds ADRB1 (Gene)
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Indacaterol (Compound) causes Cardiac disorder (Side Effect)